Executive Summary

1.7 USD Billion in 2025, the AI-Powered Oncology Diagnostics Market is expected to grow at a CAGR of 22.4% to reach 13.1 USD Billion by 2035.

Extended compliance timelines under the EU’s Digital Omnibus on AI, which push conformity assessment for CE-marked diagnostic software to August 2028, are easing near-term deployment friction for imaging and pathology vendors, while growing digital pathology and whole-slide-imaging infrastructure widens the installed base feeding AI image-analysis software used across histopathology and companion-diagnostic workflows.

North America held 41.0% of the market in 2025, ahead of Europe at 29.0% and Asia Pacific at 21.0%. Software, spanning AI/ML algorithm platforms and image-analysis tools, led the offering axis, while breast cancer diagnostics anchored demand on the indication axis as a standard-of-care adjunct to biopsy-based histopathology.

IVDR Article 110’s staggered deadlines, running from May 2025 through May 2028, constrain notified-body capacity and slow De Novo and PMA-track certification of pathology-based AI tools bound for the US FDA and EU markets. Reimbursement pathway design, including CPT-code coverage decisions and payer market-access terms, is displacing price as the axis of vendor differentiation; clinical-validation depth and regulatory clearance status still outweigh algorithm-sensitivity claims alone.

Key Takeaways

• The market stood at USD 1.74 Billion in 2025 and is forecast to reach USD 13.13 Billion by 2035, a CAGR of 22.4%.
• Software is the largest offering category.
• Breast Cancer is the largest cancer type category.
• The largest region is North America, at 41.0% in 2025.
• 10 suppliers are profiled.

Market Definition and Scope

The AI-Powered Oncology Diagnostics Market covers software, hardware and services that detect, classify and characterize tumors from radiology images, digital pathology slides and genomic data. It spans AI/ML algorithm platforms, image-analysis and workflow software, imaging scanners and digitizers, and the deployment and support services hospitals and diagnostic labs need to deploy these tools across breast, lung, colorectal, prostate and other cancers.

Excluded are non-AI diagnostic imaging equipment, standalone genomic sequencers without oncology-specific algorithms, and general hospital IT systems that do not perform cancer detection, classification or case-management functions.

Growth Drivers and Restraints

Extended AI Act Compliance Timelines Are Buying Diagnostic Software Vendors a Longer Market-Access Runway

The Digital Omnibus on AI, adopted by the European Parliament and Council, postpones the AI Act’s high-risk conformity-assessment obligations for CE-marked diagnostic software embedded in medical devices from 2 August 2027 to 2 August 2028, while Article 50 transparency duties still take effect on 2 August 2026. That gap gives image-analysis and workflow-software vendors an additional twelve months to sequence AI Act documentation behind their existing MDR/IVDR technical files rather than filing both in parallel, easing the market-access cost that falls hardest on smaller pathology-software developers seeking CE marking through a notified body.

Digital Pathology and Whole-Slide-Imaging Buildout Is Pulling Through AI Image-Analysis Software

As hospitals and diagnostic labs add whole-slide-imaging scanners and radiology digitizers to convert glass slides and film into analyzable digital files, each new scanner creates a captive channel for the AI/ML algorithm platforms and image-analysis software layered on top of it. That pull-through favors the software segment, which spans radiology image analysis, digital-pathology image analysis and genomic or molecular data analysis, over one-time purchases of the underlying device class, and it extends the standard of care in high-volume indications before it reaches lower-throughput ones.

Breast and Lung Cancer Screening Programs Concentrate Near-Term Hospital Demand

Breast cancer accounts for the largest share of AI-diagnostic activity on the indication axis, and hospitals remain the leading end-user group adopting these tools, concentrating early purchasing power in mammography and MRI image-analysis workflows rather than in lower-volume indications. Lung cancer screening, built around chest-CT nodule classification for non-small-cell disease, is the next largest pull on the same hospital-centric buying channel. Coverage decisions from payers such as CMS shape how quickly each indication converts from pilot use into reimbursed, standard-of-care ordering.

IVDR Recertification Deadlines Are Rationing Notified-Body Capacity for Pathology AI

Regulation (EU) 2017/746’s Article 110 transitional schedule requires class D in-vitro diagnostics, including AI-based companion diagnostics and tissue-based cancer-detection assays, to hold IVDR certification since 26 May 2025, with class C devices following by 26 May 2026. Because notified-body reviewer capacity has not scaled with the volume of legacy assays awaiting reassessment, digital-pathology and genomic-analysis vendors selling into Europe face queued certification timelines that delay label expansion and commercial launch independent of clinical readiness. Vendors pursuing the US FDA’s 510(k) or De Novo pathway instead face a different but parallel bottleneck in premarket review capacity.

AI Act Transparency Duties Add a Documentation Burden Alongside MDR/IVDR Filings

Article 50 of the AI Act imposes disclosure and labeling obligations on AI diagnostic tools from 2 August 2026, layering a second compliance track on top of existing MDR/IVDR technical files. Smaller AI/ML algorithm developers without in-house regulatory-affairs teams absorb this market-access cost disproportionately, and clinicians integrating these tools into radiology and pathology workflows face added training time to explain AI-generated outputs to patients under the new disclosure rules.

Market Trends

IVDR Class-Based Deadlines Are Reshaping Which Pathology AI Tools Reach the European Market

Legacy AI-based in-vitro diagnostics are being sorted by risk class under Regulation (EU) 2017/746, with class D companion-diagnostic and tissue-based cancer assays required to hold IVDR certification since 26 May 2025 and class C devices following by 26 May 2026. The staggered schedule is forcing digital-pathology vendors to prioritize certification of their highest-risk breast- and lung-cancer algorithms first, concentrating near-term European revenue in already-certified product lines while lower-class tools wait behind a longer notified-body queue through 2027 and 2028.

AI Act Rule Changes Are Letting Vendors Decouple Software Compliance From Device Certification

The Digital Omnibus on AI, agreed by the European Parliament and Council, separates AI Act timelines from MDR/IVDR ones by pushing conformity assessment for embedded high-risk diagnostic software from 2 August 2027 to 2 August 2028, even as Article 50 transparency duties start on 2 August 2026. That split lets imaging and pathology software vendors launch on MDR/IVDR approval first and add AI Act documentation afterward, shortening the path from CE marking to clinical deployment through the rest of the forecast period.

Breast-Cancer Screening in Hospital Settings Is Setting the Template for AI Diagnostic Adoption

Breast cancer holds the largest share of AI-diagnostic activity, and hospitals remain the leading end-user group deploying these tools, according to reported market activity. That combination is shaping vendor go-to-market strategy: mammography and breast-MRI image-analysis products are launching first inside hospital radiology and pathology departments, with lung, colorectal and prostate applications following the same hospital-led adoption path rather than moving first through ambulatory or homecare settings.

Segment Analysis

By Offering

• Software (largest) – Algorithms and platforms that analyze medical images, pathology slides, or genomic data to detect, classify, or characterize tumors

• AI/ML Algorithm Platforms
• Image Analysis & Interpretation Software

• Radiology Image Analysis
• Digital Pathology Image Analysis
• Genomic/Molecular Data Analysis

• Workflow & Case Management Software
• Reporting & Visualization Software
• Data Integration & Interoperability Software
• Hardware – Physical equipment such as imaging scanners, digital pathology scanners, and computing infrastructure that captures or processes oncology diagnostic data

• Imaging Systems
• Scanners & Digitizers

• Whole Slide Imaging Scanners
• Radiology Digitizers

• Computing & Processing Units
• Storage & Networking Equipment
• Services – Implementation, integration, training, and maintenance support that helps healthcare providers deploy and operate AI oncology diagnostic tools

• Deployment & Integration Services
• Training & Support Services
• Consulting Services
• Maintenance & Upgrade Services

Software led the AI-powered oncology diagnostics market in 2025, ahead of hardware and services. Providers already own the CT scanners, digital pathology scanners and compute infrastructure the algorithms run on, so software is the layer still being procured, typically under a per-study or subscription license that ties spend to case volume rather than a single capital outlay. That model gives vendors recurring revenue and gives hospitals a lower point of entry, concentrating value in the algorithm rather than the box beneath it. Services is growing fastest. Providers scaling AI across radiology and pathology departments need repeated integration, model validation and staff training rather than a one-off install, and each new indication or site added to a deployment recreates that work. That keeps services expanding ahead of the hardware it supports.

By Cancer Type

• Breast Cancer (largest) – A malignant tumor forming in breast tissue, screened and diagnosed using mammography, ultrasound, and MRI images that AI algorithms analyze to flag suspicious lesions

• Hormone Receptor-Positive Breast Cancer
• Triple-Negative Breast Cancer
• Ductal Carcinoma In Situ (DCIS)
• Lung Cancer – A malignant tumor originating in lung tissue, detected through chest CT and X-ray scans that AI software screens for nodules and classifies as benign or cancerous
• Non-Small Cell Lung Cancer (NSCLC)

• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Small Cell Lung Cancer (SCLC)
• Colorectal Cancer – A malignant tumor of the colon or rectum, identified via colonoscopy imaging and pathology slides that AI tools scan to spot polyps and abnormal tissue

• Colon Cancer
• Rectal Cancer
• Prostate Cancer – A malignant tumor in the prostate gland, evaluated using MRI scans and biopsy specimens that AI diagnostic platforms assess to grade tumor aggressiveness and location

• Localized Prostate Cancer
• Locally Advanced Prostate Cancer
• Metastatic Prostate Cancer
• Other Cancers – A grouping of remaining malignancies, including skin, blood, and organ-specific tumors, diagnosed with AI-assisted imaging and pathology tools tailored to each cancer type

• Ovarian Cancer
• Pancreatic Cancer
• Liver Cancer
• Gastric Cancer
• Cervical Cancer

Breast cancer led the market in 2025, the largest of the named cancer types. Its screening base does the work: mammography generates a steady stream of standardized images for models to train and run on, and double-reading requirements in established screening programs create a direct, reimbursable slot for an AI second reader. Lung cancer is growing fastest. Expanding low-dose CT screening eligibility is producing more scans to triage, and the diagnostic complexity of subtyping non-small cell lung cancer is pushing providers toward tools that can flag likely histology ahead of biopsy, shortening the path from scan to tissue diagnosis.

Regional Analysis

North America

41.0% of 2025 revenue was earned here, or USD 0.71 Billion.

Europe

The region took 29.0% of 2025 revenue, or USD 0.50 Billion.

Asia Pacific

The third-largest regional market, Asia Pacific accounted for 21.0% in 2025 and USD 0.37 Billion.

Competitive Landscape

The AI-powered oncology diagnostics market is fragmented, spanning diagnostics-focused specialists, imaging OEMs, and platform technology vendors supplying the compute layer beneath clinical algorithms. Competition centers on clinical validation and regulatory clearance status first: an algorithm’s label and the population it was validated against determine whether a hospital or lab can adopt it at all, ahead of price. Workflow integration matters nearly as much – tools that slot into existing PACS, LIS and reporting systems win deployment over standalone software requiring separate infrastructure, and installed base compounds this for imaging OEMs that can bundle diagnostic AI onto scanners already placed in provider networks. No single vendor dominates; the market is led instead by a group of established players: Tempus AI, Paige AI, PathAI, Guardant Health, Exact Sciences, Siemens Healthineers, GE HealthCare, IBM, NVIDIA, and Qure.ai Technologies. These span genomic and pathology data platforms, whole-slide imaging specialists, diversified device manufacturers, and compute infrastructure providers, reflecting a value chain split across data generation, model development and clinical deployment rather than concentrated in one layer.

Strategic Outlook

The clearest whitespace sits in lung cancer diagnostics, where expanding low-dose CT screening eligibility is generating scan volume faster than radiology staffing can absorb it. Diagnostics specialists with cleared triage and subtyping algorithms stand to benefit most, provided national screening programs continue funding the imaging that AI models depend on to run.

Software and services are likely to keep gaining share of spend relative to hardware, since most large providers already hold the imaging infrastructure. Competitive advantage should tilt further toward regulatory clearance breadth and workflow integration, and away from accuracy claims alone.

AI-Powered Oncology Diagnostics Market Report Scope